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Abstract  1 
Inflammatory cell infiltration in tumor stroma may represent the interaction between 2 
the tumor and the immune system. The significance of immunoglobulin (Ig)G4+ 3 
plasmacytic infiltration, however, is poorly understood. Here, we analyzed the number 4 
of stromal IgG4+ plasma cells and the IgG4/IgG ratio of plasma cells in 294 primary 5 
non-small cell lung cancers (NSCLC) using tissue microarray (TMA) and conventional 6 
surgical specimens. In TMA, 35 (12%) cases of NSCLC revealed more than 20 IgG4+ 7 
plasma cells per high-power field. In surgical specimens, most (97%) of those IgG4+ 8 
plasma cell-enriched cases showed obliterative phlebitis or arteritis, one of the key 9 
morphologic features of IgG4-related disease, within or at the periphery of the tumor. 10 
Clinically, none of the patients showed symptoms associated with IgG4-related 11 
systemic diseases. In patients with stage I squamous cell carcinoma, IgG4-enriched 12 
stroma was significantly associated with a favorable prognosis (p = 0.04). In 13 
conclusion, considerable IgG4+ plasma cell infiltration can be seen in a minority of 14 
cases of NSCLC, and might contribute to prognostic modulation of NSCLC.  15 
  16 
4 
Introduction 1 
Despite a number of recent studies focused on the tumor microenvironment, the role 2 
of plasma cells in cancer is not well understood [1]. The class and subclass of 3 
immunoglobulin (Ig) produced by plasma cells are defined primarily by their heavy 4 
chain constant domain sequences, which affect the function of the antibody [2]. IgG4, 5 
the least abundant subclass in the IgG class, shows weak or negligible binding ability 6 
to both C1q and Fcγ receptors compared with the other IgG subclasses, which leads 7 
to a limited capacity to activate the classical complement pathway [2,3]. Thus, until 8 
recently, it was believed that IgG4 plays only a limited role in immune activation [3]. As 9 
a consequence of the current familiarity of IgG4-related diseases (IgG4-RD) to 10 
pathologists and the widespread use of anti-IgG4 antibody for immunohistochemical 11 
staining, cases of carcinoma accompanied by severe IgG4+ plasma cell infiltration in 12 
patients with or without a medical history of IgG4-RD have been identified [4-9], 13 
although the prevalence and significance of this phenomenon remain unclear.  14 
Differential diagnosis of IgG4-RD and cancers can be problematic, since IgG4-RD 15 
often forms tumefactive lesions and peritumoral desmoplastic tissue can mimic 16 
IgG4-RD when there is an abundance of IgG4+ plasma cells in a biopsy specimen. 17 
Some morphologic findings such as obliterative phlebitis are considered to be rather 18 
more specific to IgG4-RD than to cancer, but existing evidence supporting this idea 19 
5 
seems weak [10]. Serum IgG4 concentration is a helpful laboratory finding to 1 
differentiate IgG4-RD and cancer, but it is not always elevated in patients with 2 
IgG4-RD, while it can be elevated in cancer patients without IgG4-RD [4,8]. In addition, 3 
clinicians must keep in mind the possibility of synchronous cancer and IgG4-RD [11].  4 
In this study, we identified cases of lung cancer with stromal IgG4+ plasma cell 5 
infiltration using tissue microarray (TMA). We analyzed the clinicopathologic 6 
characteristics of these cases to investigate the relevance of lung cancer and IgG4+ 7 
plasma cells. 8 
 9 
Materials and Methods 10 
TMA  11 
Paraffin-embedded tumor blocks from 363 cases of lung cancer surgically resected 12 
from different patients in Kyoto University Hospital between 2001 and 2007 were 13 
selected from the electronic pathology files of Kyoto University Hospital for 14 
construction of TMA, with the patients’ consent. TMAs were constructed by 2 of the 15 
authors (A.Y. and S.S.) basically using the approach described by Kononen et al. [12]. 16 
Briefly, the most morphologically representative region of the tumor was selected on a 17 
hematoxylin and eosin (H&E)-stained slide. Then, a tissue core of 2 mm in diameter 18 
was punched out from each donor tumor block using a thin-walled stainless steel 19 
6 
needle for TMA construction (Azumaya, Tokyo, Japan), and arrayed in a recipient 1 
paraffin block. Small cell carcinomas, recurrent carcinomas, carcinomas with 2 
neoadjuvant chemotherapy and cases with multiple carcinomas (both synchronous 3 
and metachronous) were excluded from this study, but were established in TMA for 4 
another study (n=45). 5 
 6 
Immunohistochemistry  7 
Immunostains against IgG4 and IgG using mouse anti-human IgG4:HRP 8 
(MCA2098P; dilution 1:200; AbD Serotec, Oxford, UK) and IgG (immunoglobulin G) 9 
(polyclonal; dilution 1:2 of prediluted product; Ventana, Tucson, AZ, USA) were 10 
performed on an autoimmunostainer (Ventana XT System Benchmark; Ventana 11 
Medical Systems).  12 
  13 
Evaluation of immunohistochemistry 14 
In TMA sections, we regarded tumors infiltrated by more than 20 IgG4+ plasma 15 
cells per high-power field (HPF) (x40 objective lens with field number 22) as IgG4+ 16 
cell-enriched cases, since this criterion is used for diagnosing IgG4-RD in lung biopsy 17 
specimens [10]. To calculate the IgG4/IgG ratio in each TMA section, the total 18 
numbers of IgG4+ and IgG+ plasma cells per core were counted manually under a 19 
7 
light microscope by M.F. and A.Y. For those IgG4+ cell-enriched cases with >25% 1 
IgG4/IgG ratio, immunohistochemistry for IgG4 and IgG was performed on the original 2 
surgical specimens to extract the cases fulfilling the quantitative criteria for IgG4-RD 3 
(>50/HPF of plasma cells with IgG4/IgG ratio >40%) [10]. In each case, IgG4 and IgG 4 
were counted in the region most highly stained for IgG4 in three HPFs to calculate the 5 
IgG4/IgG ratio.  6 
 7 
Histologic evaluation 8 
Histologic types of lung cancers were determined according to the 2004 WHO 9 
classification [13]. In adenocarcinomas, the predominant histologic subtype or variant 10 
in each case was identified according to the new lung adenocarcinoma classification 11 
proposed by the International Association for the Study of Lung Cancer, American 12 
Thoracic Society and European Respiratory Society (IASLC/ATS/ERS classification) 13 
[14], and it was also graded as well differentiated (G1), moderately differentiated (G2) 14 
and poorly differentiated (G3) based on the 2004 WHO classification by three of the 15 
authors (M.F., A.Y. and S.S.) [13].  Squamous cell carcinomas were not graded in 16 
this study, since the stage of the disease and the performance status at diagnosis 17 
remain the most powerful prognostic indicators, instead of the current grading system 18 
mainly based on the degree of keratinization [13]. IgG4+ cell-enriched cases were 19 
8 
evaluated by two of the authors (M.F. and A.Y.) for the presence of obliterative 1 
phlebitis/arteritis and increased number of eosinophils, which we defined as more 2 
than 50 eosinophils per 10 HPFs.  3 
 4 
Clinical information 5 
The electronic chart of Kyoto University Hospital, the electronic database of the 6 
Department of Thoracic Surgery of Kyoto University Hospital and the electronic 7 
pathology database of Kyoto University Hospital were used to search for patients’ 8 
prognosis and medical history.  9 
 10 
Somatic EGFR, KRAS and p53 mutations 11 
EGFR, KRAS and p53 mutation analyses were carried out in selected cases by 12 
methods described previously [15,16].  13 
 14 
Statistical analysis 15 
GraphPad Prism (GraphPad Software, San Diego, CA, USA) and JMP Start 16 
Statistics (Statistical Discovery Software SAS Institute, Cary, NC, USA) were used for 17 
statistical analyses. Comparisons between two groups were performed with Fisher’s 18 
exact test or Mann-Whitney’s test to analyze categorical variables and continuous 19 
9 
variables, respectively. The Kaplan-Meier method was used to evaluate patients’ 1 
prognosis and log-rank tests were used to compare the survival rates among groups. 2 
Logistic regression analysis was performed to examine the interaction of the multiple 3 




TMA cores that were not completely enclosed on the sections or did not include 8 
viable tumor on the sections were excluded from this study (n=24). As a result, 294 9 
primary non-small cell lung carcinomas (NSCLC) were extracted. The median 10 
follow-up period of patients was 1748 days (range: 7-3805). 11 
The 294 lung cancers consisted of 233 adenocarcinomas (79.3%), 52 squamous 12 
cell carcinomas (17.7%) and 9 other NSCLC (3.1%) (6 large cell carcinomas, 2 13 
sarcomatoid carcinomas and 1 adenosquamous carcinoma). According to the 7th 14 
UICC TNM classification [17], 215 cases (73.1%) were stage I, 37 cases (12.6%) 15 
were stage II, 31 cases (10.5%) were stage III and 11 cases (3.7%) were stage IV. 16 
Among the 233 adenocarcinomas, 60 cases (25.8%) were G1, 90 cases (38.6%) 17 
were G2 and 83 cases (35.6%) were G3. The median numbers of IgG4+ and IgG+ 18 
plasma cells in the TMA core were 0 (range: 0-570) and 134 (range: 0-2178), 19 
10 
respectively. None of the 294 patients had IgG4-RD in their medical history and serum 1 
IgG4 concentration was not measured in any of the patients. 2 
In adenocarcinomas, mutation analysis of EGFR, KRAS and p53 was performed in 3 
213 cases, 213 cases and 129 cases, respectively, and the mutation was confirmed in 4 
102 cases (47.9%), 23 cases (10.8%) and 31 cases (24.0%), respectively. 5 
 6 
Lung cancers with IgG4+ cell enrichment (n=35) 7 
Out of 294 cases, 35 cases (11.9%) were IgG4+ cell-enriched, including 17 8 
adenocarcinomas (7.3% of all adenocarcinomas), 17 squamous cell carcinomas 9 
(32.7% of all squamous cell carcinomas) and 1 adenosquamous carcinoma. Among 10 
the 17 adenocarcinomas, 15 cases were G3 and 2 were G2. G1 adenocarcinoma was 11 
not observed. 12 
The median number of original tumor slides observed per case was 3 (range: 1-9) 13 
and Victoria blue H&E stain and/or Elastica van Gieson stain was performed in all but 14 
1 case. Fibrosis was evident in cancer stroma of all 35 cases, but none of them 15 
showed storiform pattern fibrosis. Obliterative phlebitis/arteritis was found in 34 cases 16 
(97.1%) associated with desmoplasia. An increased number of eosinophils was seen 17 
in 3 cases (8.6%). In all 35 cases, pathological change for which IgG4-RD was 18 
suspected was absent in non-neoplastic lung tissue surrounding the cancers.  19 
11 
The result of comparison between IgG4+ cell-enriched cases and the cases with 1 
≤20 IgG4+/HPF in the TMA core is shown in Table 1. We also performed multivariate 2 
logistic regression analysis to determine which factors, among those showing 3 
statistical significance in univariate analysis, were more significantly associated with 4 
>20/HPF IgG4+ plasma cell infiltration (Table 2). This analysis revealed that 5 
squamous cell carcinoma and G3 adenocarcinoma were associated with >20/HPF 6 
IgG4+ plasma cell infiltration with high statistical significance (p<0.0001 and p=0.0013, 7 
respectively).  8 
No statistical difference in recurrence rate or death rate was observed between the 9 
two groups (Table 1). In stage I carcinoma, however, none of the 19 IgG4+ 10 
cell-enriched cases (10 G2-G3 adenocarcinomas, 8 squamous cell carcinomas and 1 11 
adenosquamous carcinoma) was associated with patient death, and only 1 squamous 12 
cell carcinoma and 1 adenocarcinoma recurred. In contrast, among 27 stage I 13 
squamous cell carcinomas with ≤20 IgG4+ plasma cells/HPF, 10 patients (37.0%) 14 
died of disease and 11 cases (40.7%) recurred. Among 110 stage I G2-3 15 
adenocarcinomas with ≤20 IgG4+ plasma cells/HPF, 13 patients (11.8%) died of 16 
disease and 29 cases (26.4%) recurred. A significant difference of overall patient 17 
survival was observed in stage I squamous cell carcinoma (p=0.0409), but this was 18 
not the case for disease-free survival rate (p=0.1053) (Figure 1). No significant 19 
12 
difference in overall survival or disease-free survival rate was observed in stage I 1 
G2-3 adenocarcinoma (p=0.3280 and p=0.4407, respectively).  2 
 3 
Lung cancers with >50 IgG4+ plasma cells/HPF and >40% IgG4/IgG plasma cells 4 
in surgical specimens (n=6) 5 
Among 35 IgG4+ cell-enriched cases in the TMA core, 12 cases were associated 6 
with >25% IgG4/IgG ratio, and 6 of them showed >50 IgG4+ plasma cells/HPF and 7 
>40% IgG4/IgG ratio in the surgical specimens. The clinicopathological features of 8 
these 6 cases are summarized in Table 3. Histologic figures of selected cases are 9 
shown in Figure 2. 10 
In comparison of these 6 cases and the other 29 IgG4+ cell-enriched cases, no 11 
statistically significant difference was obtained in any parameters shown in Table 1, 12 
except the IgG4/IgG ratio in the TMA core (median: 0.28 vs. 0.12, p=0.0062). 13 
Additionally, the numbers of cases with obliterative phlebitis/arteritis and increased 14 
number of eosinophils in these 2 groups did not differ significantly (83.3% vs. 100%, 15 
p=0.1714, and 16.7% vs. 6.9%, p=0.4417, respectively). 16 
 17 
Discussion 18 
IgG4+ plasma cell infiltration in cancer and its relevance to IgG4-RD have been a 19 
13 
matter of debate in the field of practical medicine [4-9]. Since chronic inflammation is 1 
associated with a risk of cancer development, it could be hypothesized that IgG4-RD 2 
is a source of carcinoma [11,18]. In our series, however, the idea that the patients with 3 
IgG4+ cell-enriched tumor had lung IgG4-RD seems unlikely for two main reasons. 4 
Firstly, none of the IgG4+ cell-enriched cases showed histology of IgG4-RD in the 5 
non-neoplastic lung tissue, suggesting that the cancer is the factor causing the 6 
inflammation and not the other way round. Secondly, although IgG4-RD is a systemic 7 
disease and the affected patients commonly develop multi-visceral lesions or multiple 8 
lesions in the same organ at the time of diagnosis or during the follow-up [6,19], none 9 
of the patients in our series was clinically complicated by IgG4-RD at the time of 10 
diagnosis or during the follow-up of cancer.  11 
Considering the favorable prognosis observed in IgG4-enriched stage I squamous 12 
cell carcinomas, IgG4 infiltration might cause prognostic modulation of NSCLC. At first, 13 
this result seemed to be inconsistent with the notable anti-immune function of IgG4, 14 
as seen in the transition of serum IgG4 level in immunotherapy [20]. Other previous 15 
reports, however, show that the functional role of IgG4 varies in different 16 
pathophysiological circumstances, and that IgG4 can be a pathogenic antibody in 17 
certain immunologic disorders [21-25]. Our data may suggest that IgG4 reacts against 18 
certain lung cancer antigens and damages tumor cells in spite of its poor complement- 19 
14 
and leucocyte-activating properties. By multivariate analysis, we found that squamous 1 
cell carcinomas and high-grade adenocarcinomas are more likely to be accompanied 2 
by intra-tumoral IgG4+ plasma cells; however, the reason for this tendency is unclear 3 
at present. 4 
In stage I squamous cell carcinoma, intra-tumoral IgG4+ plasma cell infiltration may 5 
be a better prognostic factor than conventional histological grade because the 6 
histological grade of lung squamous cell carcinoma is not clearly related to its 7 
prognosis [13]. IgG4+ plasma cells might have a cancer-inhibiting role in 8 
adenocarcinomas as well, but our data did not show statistical significance. In 9 
adenocarcinomas, high-grade histology or non-EGFR gene mutation may be a more 10 
powerful prognostic factor than IgG4+ cell infiltration [15,16,26]. 11 
A common histological finding of IgG4-RD is sclerosing fibrosis arranged at least 12 
focally in a storiform pattern accompanied by marked IgG4+ plasma cell infiltration, 13 
usually associated with obliterative phlebitis; however, there is variability in the 14 
findings in certain organs [10]. In lung IgG4-RD, stroriform-type fibrosis is uncommon; 15 
thus, histological findings tend to overlap with other pulmonary fibroinflammatory 16 
conditions. In the pericancerous fibrous stroma of our IgG4+ cell-enriched cancers, 17 
even obliterative phlebitis/arteritis, the histological finding of which is believed to be 18 
quite specific to lung IgG4-RD, was observed in most of the cases. Pathologists 19 
15 
should be aware of this fact when diagnosing lung IgG4-RD on biopsy specimens.  1 
In conclusion, a non-negligible minority of cases of squamous cell carcinoma and 2 
high-grade adenocarcinoma of the lung showed IgG4+ plasma cell infiltration in the 3 
stroma. Obliterative vascular changes were commonly seen in those cases without 4 
clinical evidence of IgG4-RD. Since IgG4+ cell-enriched cases were associated with 5 
favorable prognosis in stage I squamous cell carcinomas, IgG4 infiltration may be part 6 
of the anti-cancer immune response.   7 
  8 
16 
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Table legends 1 
 2 
Table 1. Comparison of lung cancers with and without >20 IgG4+ plasma cells/HPF in 3 
the tissue microarray (TMA) core (n=294). 4 
 5 
Table 2. Logistic regression analysis for estimation of significant factors related to 6 
>20/HPF intra-tumoral IgG4+ plasma cell infiltration. 7 
 8 
Table 3. Clinicopathological characteristics of 6 lung cancers that fulfilled the 9 
histological criteria of lung IgG4-RD (IgG4/IgG ratio >40% and >50/HPF IgG4+ 10 
plasma cells in surgical specimen). 11 
  12 
p 
≤20/HPF
No. of cases 259 (88.1%)
Median of IgG4/IgG ratio in TMA core
(range)
0 (0-0.75) <0.0001*
Male 144 (55.6%) 0.0005*
Median age (range) 67 (23-94) 0.1783
Never smokers 107 (41.3%) 0.0004*
Preoperative history of cancer 48 (18.5%) 0.8189
Preoperative history of asthma 8 (3.1%) 0.0417*
Preoperative history of collagen vascular
disease
9 (3.5%) 1
Preoperative history of interstitial
pneumonia
15 (5.8%) 0.7032
Squamous cell carcinomas  35 (13.5%) <0.0001*
G3  adenocarcinomas 68 (26.3%) 0.0468*
EGFR 99/199 (49.0%) 0.0524
KRAS 22/199 (11.1%) 1
 p53 26/122 (21.3%) 0.0088*
Stage I cancers 196 (75.7%) 0.0134*
Recurrence rate                  (Recurrence




Death rate                                     (Death





















 17 (48.6%) 
EGFR 3/14 (21.4%)
15 (42.9%)
Gene mutation in adenocarcinomas
Variable Odds ratio 95% confidence interval p







Squamous cell carcinoma 15.4307 4.5863-71.6024 <0.0001*




 * Statistically significant.
Table 2
Case No. 1 2 3 4 5 6
Sex Male Male Male Male Male Male
Age at surgery 59 61 61 65 72 75
Smoking status Current Former Former Former Never Current











Site Right upper lobe Left upper lobe Right lower lobe Right upper lobe Left upper lobe Left lower lobe

















Present Present Absent Present Present Present
 Eosinophilic infiltration
>50/10 HPF
Absent Absent Absent Present Absent Absent
IgG4/IgG ratio in TMA
core (%)
206/820 (25.1) 570/1204 (47.3) 172/625 (27.5) 258/1012 (25.5) 216/648 (33.3) 348/1211 (28.7)
 IgG4/IgG ratio in surgical
specimen (%)
51.7/103.7 (49.9) 80.0/137.0 (58.4) 67.7/146.7 (46.1) 53.3/125.3 (42.5) 69.7/170.7 (40.8) 50.6/105.3 (48.1)
EGFR Not done Wild Wild Wild Mutated Wild
KRAS Not done Mutated Wild Wild Wild Wild
p53 Not done Not done Mutated Wild Not done Wild
Recurrence of lung
carcinoma
Absent Absent Absent Absent Present Absent
Outcome Alive Alive Alive Alive Died of disease Alive
Follow-up period (days) 3480 1666 2747 2002 376 1468
Table 3
22 
Figure legends 1 
 2 
Figure 1 Kaplan-Meier survival curves of 35 patients with stage I squamous cell 3 
carcinomas separated by the number of IgG4+ plasma cells/HPF in the tissue 4 
microarray core (>20/HPF vs. ≤20/HPF). (A) Overall survival curves (log-rank test, 5 
p=0.0409), and (B) disease-free survival curves (log-rank test, p=0.1053). 6 
  7 
Figure 2 Histology of lung cancers fulfilling the histological criteria for lung IgG4-RD, 8 
(A)-(E) case 2 and (F)-(H) case 4.  9 
(A) Case 2, solid predominant G3 adenocarcinoma (×20).  10 
(B) Higher-magnification image of boxed area in (A) (×100).  11 
(C) Intratumoral obliterative phlebitis (×100).  12 
(D) >50/HPF IgG4+ plasma cells in the cancer stroma (×200).  13 
(E) IgG immunostain at the same area as in (D), with IgG4/IgG ratio >40% (×200).  14 
(F) Case 4, squamous cell carcinoma (×40).  15 
(G), (H) Higher magnification of the areas demarcated by boxes in (F); obliterative 16 
vasculitis and eosinophilic infiltration are shown, respectively (×200 and ×400).  17 
 18 
 19 










